Where I see patients (3)
Selected research
-
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
Blood
-
Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.
European journal of haematology
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
Blood
Contact me
Learning never stops
Our classroom and bedside classes help kids get credit and keep learning during treatment.
See our school program
